CDC-RFA-GH21-2160: Hospital Based Birth Defects Surveillance in Kampala, Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - CGH notices from 2021.
Centers for Disease Control - CGH offered grants to the applicants described in the notice. It expected to make one award. Applications closed on May 4, 2021.
From the official notice on Grants.gov, last changed March 25, 2021. Checked November 7, 2026.
- Expected awards1
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 4, 2021 |
|---|---|
| Deadline | May 4, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants that can apply for this NOFO are:Makerere University-Johns Hopkins University Research Collaboration (MU-JHU)
Is this a realistic fit?
- Most of the program's money (62% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $1,000,000 for Year 1, subject to the availability of funds. This NOFO aims to: 1) continue a birth defects surveillance system in at least four main hospitals in Kampala, Uganda focusing on major external structural birth defects; and 2) determine if maternal use of dolutegravir, cotrimoxazole or other medications during very early pregnancy is associated with a higher risk of birth defects in newborns. Results from these activities will provide background rates of birth defects in Kampala, provide baseline estimates of maternal medication use to treat HIV in pregnancy, and ascertain any correlation between medication use and external birth defects. WHO and PEPFAR will use these findings to inform guidance regarding use of specific HIV medications during pregnancy.
Who has won Global AIDS grants before
From fiscal 2021 to 2025, Global AIDS (93.067) awarded $7.6 billion across 521 grant awards, an average of $14.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 32 | $684 million |
| Elizabeth Glaser Pediatric AIDS Foundation | District of Columbia | 13 | $387 million |
| Management and Development for Health | 5 | $282 million | |
| Apin Public Health Initiatives LTD/Gte | 4 | $209 million | |
| University of Washington | Washington | 8 | $195 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-GH21-2160 still open?
No. It closed on May 4, 2021.
Who can apply for Hospital Based Birth Defects Surveillance in Kampala, Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)?
Centers for Disease Control - CGH accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Hospital Based Birth Defects Surveillance in Kampala, Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)?
Closed May 4, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Global AIDS grants before?
The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, Elizabeth Glaser Pediatric AIDS Foundation, Management and Development for Health. The program made 521 awards worth $7.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)